Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Christgen

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Breast Cancer Research : BCR|September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialCornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
Cancer|August 12, 2020
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancerMatthias Christgen, Oleg Gluz, Nadia Harbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast CancerUlrike Nitz, Oleg Gluz, Michael Clemens, et al.
Breast Cancer Research and Treatment|January 12, 2019
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
International Journal of Cancer|June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trialOleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
British Journal of Cancer|February 23, 2022
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS CAmelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, et al.
Breast Cancer Research and Treatment|July 1, 2017
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
JCO Clinical Cancer Informatics|November 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerDaniel Kates-Harbeck, Hans Kreipe, Oleg Gluz, et al.
The Lancet. Oncology|April 11, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trialUlrike Nitz, Oleg Gluz, Monika Graeser, et al.
JAMA Oncology|May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical TrialOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Breast Cancer Research : BCR|September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialCornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
Cancer|August 12, 2020
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancerMatthias Christgen, Oleg Gluz, Nadia Harbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast CancerUlrike Nitz, Oleg Gluz, Michael Clemens, et al.
Breast Cancer Research and Treatment|January 12, 2019
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
International Journal of Cancer|June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trialOleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
British Journal of Cancer|February 23, 2022
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS CAmelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, et al.
Breast Cancer Research and Treatment|July 1, 2017
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
JCO Clinical Cancer Informatics|November 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerDaniel Kates-Harbeck, Hans Kreipe, Oleg Gluz, et al.
The Lancet. Oncology|April 11, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trialUlrike Nitz, Oleg Gluz, Monika Graeser, et al.
JAMA Oncology|May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical TrialOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Pageof 11